Westminster Hall is an alternative Chamber for MPs to hold debates, named after the adjoining Westminster Hall.
Each debate is chaired by an MP from the Panel of Chairs, rather than the Speaker or Deputy Speaker. A Government Minister will give the final speech, and no votes may be called on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
The Parliamentary Under-Secretary of State for Health and Social Care (Ashley Dalton)
It is a pleasure to serve under your chairmanship, Mr Efford. I thank you and other Members for persevering despite my slightly tardy arrival, which was due, ironically, to the somewhat unpredictable effects of cancer chemotherapy. I am well, however, and have enjoyed the debate immensely.
Before I begin, I pay tribute to all our NHS staff, our care workers and everyone serving our hospices for their work over the Christmas and new-year period. I am grateful to the hon. Member for Wokingham (Clive Jones) for securing this debate, and for doing his bit to keep up morale at the Royal Berkshire hospital on Christmas eve. I thank all Members for their contributions, and acknowledge all their personal stories and the stories they shared of their constituents. Such a wide range of issues has been raised; I will endeavour to respond to all questions, but given the time pressure, I will follow up in writing to any Members whose questions I do not cover.
I will address each of the issues raised by the hon. Member for Wokingham in order. He is right that progress has been uneven across different types of cancer, and that less survivable cancers can be difficult to identify as the symptoms may mirror those of a host of other illnesses. To boost the diagnosis of cancers that are harder to catch at an earlier stage, we have rolled out the non-specific symptom pathways, with 115 NSS services now live. NSS pathways provide a referral route for patients whose symptoms do not fit under a specific cancer pathway. They are making diagnosis smoother and faster for patients whose symptoms are not as clear.
The Government are proud to support the Rare Cancers Bill introduced by my hon. Friend the Member for Edinburgh South West (Dr Arthur). Baroness Elliott will move its Second Reading in the other place on Friday next week.
As a cancer patient myself, I was proud to stand on a manifesto to tackle the biggest killers. My right hon. and learned Friend the Prime Minister reaffirmed that pledge just over a year ago, through our plan for change. Although the all cancer survival rate is the best it has ever been, less survivable cancers have just a 16% five-year survival rate, accounting for 67,000 deaths a year. And demand is rising: each day there are around 13,000 urgent referrals for suspected cancer. That is up almost 3,000 a day since 2019.
My officials, including those leading on the national cancer plan, are carefully considering every one of the APPG’s recommendations. Although I cannot go into detail today, I assure Members that rare and less survivable cancers will feature heavily in the new cancer plan. The Government are asking the NHS, charities and all my colleagues in this place to join in a new national effort, spearheaded by the national cancer plan, which we will publish in just a few short weeks, in early February. I can confirm that there is no truth in the rumour that it is being delayed to March. The plan will cover the entirety of the cancer pathway, from referral and diagnosis to treatment and ongoing care. We want patients to have access to the latest treatments and technology, and to receive the highest quality of care.
We made genomics one of the five big bets in our 10-year plan for health, setting out how we will harness it to create a genomics population health service and support innovation. In July last year, we launched the groundbreaking national inherited cancer predisposition register, so that we can keep track of people with genes that put them at risk. That brings me to a wider point about diagnostics and primary care. We have introduced Jess’s rule, named after Jess Brady, to prompt GPs to investigate further when a patient presents with the same symptoms or concerns more than twice. We have also boosted community diagnostic centres and invested an extra £889 million in general practice. We are committed to ensuring that GPs have the right training and systems to identify cancer symptoms, and we will continue to support the use of clinical decision support tools.
On research and innovation, the Department of Health and Social Care invests over £1.6 billion a year in research through the National Institute for Health and Care Research. At over £141 million in the last financial year, cancer research is a major area of NIHR spending. Just last month, the NIHR launched a pioneering new £13.7 million brain tumour research consortium to accelerate research into new treatments.
On the question from my hon. Friend the Member for Mitcham and Morden (Dame Siobhain McDonagh), I understand that the NIHR chief executive officer, Professor Lucy Chappell, has recently written to her, and I will follow up in writing to respond to my hon. Friend’s question and to explain the process of submitting a bid to the NIHR in detail.
In 2024, the NIHR and the Office for Life Sciences announced nearly £11 million to support the further testing of innovations to help to increase the early detection and diagnosis of cancer. That includes funding for research into the new breath test for multiple gastrointestinal cancers and to look at how we can roll it out in primary care.
People watching at home might be thinking, “Well, what happens with all this research?” So let me briefly give a real-world example of implementation: the Cytosponge is a simple test that can identify conditions that are a precursor to oesophageal cancer. The NIHR, alongside Cancer Research UK, funded research into the development of this “sponge on a string”. This year will see a new NHS pilot of its use in high street pharmacies, supporting the shift in the delivery of care from hospitals to community as part of our 10-year health plan.
The Government are developing a palliative care and end-of-life care modern service framework, with publication planned for spring this year. The framework will align with the ambitions of the 10-year health plan, which prioritises shifting care out of hospitals and into community settings to ensure personalised, compassionate support for individuals of all ages and their families.
The Government were elected on a manifesto to tackle the biggest killers, including cancer. I am proud to stand here today, after 18 months, and say that we can see some green shoots of recovery across the health service, with 135,000 more cancer diagnoses within the 28-day target. That is partly driven by over 100 community diagnostic centres opening at evenings and on weekends, and new surgical hubs to treat people faster.
With the publication of our national cancer plan, 2026 could be a decisive year for cancer care. I look forward to working with the hon. Member for Wokingham, the APPG, my hon. Friend the Member for Edinburgh South West and all other Members to make sure that we keep our momentum into the new year and bring about real change.